Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis
作者： Alimuddin Zumla , Martin Rao , Ernest Dodoo , Markus Maeurer
DOI: 10.1186/S12916-016-0635-1
关键词:
摘要: Treatment of multidrug-resistant tuberculosis (MDR-TB) is extremely challenging due to the virulence etiologic strains Mycobacterium (M. tb), aberrant host immune responses and diminishing treatment options with TB drugs. New regimens incorporating therapeutics targeting both M. tb factors are urgently needed improve clinical management outcomes MDR-TB. Host-directed therapies (HDT) could avert destructive tuberculous lung pathology, facilitate eradication tb, survival prevent long-term functional disability. In this review we (1) discuss use HDT for cancer other infections, drawing parallels precedent they set MDR-TB treatment, (2) highlight preclinical studies pharmacological agents commonly used in practice which have potential, (3) outline developments cellular therapy promote clinically beneficial immunomodulation patients pulmonary The HDTs as adjuncts requires urgent evaluation.
biomedcentral.com
springer.com
core.ac.uk
dnb.de参考文章(146)
Lavanya Joshi, Lakshmi Kiran Chelluri, Sumanlatha Gaddam, Mesenchymal Stromal Cell Therapy in MDR/XDR Tuberculosis: A Concise Review. Archivum Immunologiae Et Therapiae Experimentalis. ,vol. 63, pp. 427- 433 ,(2015) , 10.1007/S00005-015-0347-9
Jacob Nelson, Kelsey Roe, Beverly Orillo, Pei-Yong Shi, Saguna Verma, None, Combined treatment of adenosine nucleoside inhibitor NITD008 and histone deacetylase inhibitor vorinostat represents an immunotherapy strategy to ameliorate West Nile virus infection. Antiviral Research. ,vol. 122, pp. 39- 45 ,(2015) , 10.1016/J.ANTIVIRAL.2015.07.008
S.T.R. Pinho, P. Rodrigues, R.F.S. Andrade, H. Serra, J.S. Lopes, M.G.M. Gomes, Impact of tuberculosis treatment length and adherence under different transmission intensities. Theoretical Population Biology. ,vol. 104, pp. 68- 77 ,(2015) , 10.1016/J.TPB.2015.06.004
Eric M Mortensen, Marcos I Restrepo, Antonio Anzueto, Jacqueline Pugh, The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia Respiratory Research. ,vol. 6, pp. 82- 82 ,(2005) , 10.1186/1465-9921-6-82
Paul A. Marks, Victoria M. Richon, Wm Kevin Kelly, Judy H. Chiao, Thomas Miller, Histone deacetylase inhibitors: development as cancer therapy. Novartis Foundation symposium. ,vol. 259, pp. 269- 284 ,(2004) , 10.1002/0470862637.CH20
Javier O. Jurado, Ivana B. Alvarez, Virginia Pasquinelli, Gustavo J. Martínez, María F. Quiroga, Eduardo Abbate, Rosa M. Musella, H. Eduardo Chuluyan, Verónica E. García, Programmed Death (PD)-1:PD-Ligand 1/PD-Ligand 2 Pathway Inhibits T Cell Effector Functions during Human Tuberculosis Journal of Immunology. ,vol. 181, pp. 116- 125 ,(2008) , 10.4049/JIMMUNOL.181.1.116
Brenda Kwak, Flore Mulhaupt, Samir Myit, François Mach, Statins as a newly recognized type of immunomodulator Nature Medicine. ,vol. 6, pp. 1399- 1402 ,(2000) , 10.1038/82219
Lisa Heitmann, Mahin Abad Dar, Tanja Schreiber, Hanna Erdmann, Jochen Behrends, Andrew NJ Mckenzie, Frank Brombacher, Stefan Ehlers, Christoph Hölscher, The IL-13/IL-4Rα axis is involved in tuberculosis-associated pathology The Journal of Pathology. ,vol. 234, pp. 338- 350 ,(2014) , 10.1002/PATH.4399
W. Berger, M. T. M. De Chandt, C. B. Cairns, Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease. International Journal of Clinical Practice. ,vol. 61, pp. 663- 676 ,(2007) , 10.1111/J.1742-1241.2007.01320.X
Shreemanta K. Parida, Thomas Poiret, Liu Zhenjiang, Qingda Meng, Jan Heyckendorf, Christoph Lange, Aditya S. Ambati, Martin V. Rao, Davide Valentini, Giovanni Ferrara, Elena Rangelova, Ernest Dodoo, Alimuddin Zumla, Markus Maeurer, T-Cell Therapy: Options for Infectious Diseases Clinical Infectious Diseases. ,vol. 61, ,(2015) , 10.1093/CID/CIV615